Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report
Sign Up to like & getrecommendations! Published in 2018 at "Case Reports in Oncology"
DOI: 10.1159/000489603
Abstract: There are various mechanisms underlying the resistance of EGFR-mutant lung adenocarcinoma to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). We herein report a case of pulmonary adenocarcinoma with EGFR mutation (exon 19 deletion and… read more here.
Keywords: treatment; transformation; case; osimertinib treatment ... See more keywords
Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations
Sign Up to like & getrecommendations! Published in 2022 at "Oncotarget"
DOI: 10.18632/oncotarget.28210
Abstract: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Around 30% of patients are diagnosed with early disease and 60% after the tumour has spread to a different part of the… read more here.
Keywords: adjuvant osimertinib; early stage; stage nsclc; osimertinib treatment ... See more keywords
Does osimertinib treatment discriminate young patients?
Sign Up to like & getrecommendations! Published in 2019 at "Journal of thoracic disease"
DOI: 10.21037/jtd.2019.08.118
Abstract: Osimertinib (AZD9291 or TAGRISSO™) is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) developed to overcome T790M-induced resistance, which accounts for approximately 60% of resistant cases after 1 st generation EGFR-TKI treatment. Beyond… read more here.
Keywords: treatment discriminate; treatment; osimertinib treatment; young patients ... See more keywords
Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.986962
Abstract: Background: In this pooled analysis, the aim was to investigate the clinicopathological characteristics of patients with uncommon epidermal growth factor receptor (EGFR) (ucm-EGFRms) along with their treatment responses and survival following osimertinib treatment. Methods: Univariate… read more here.
Keywords: osimertinib treatment; following osimertinib; pooled analysis; mutation ... See more keywords